Here we present three important innovations in the nephrology field. The first one concerns the management of autosomal dominant polycystic kidney disease, and in particular the treatment by tolvaptan, a drug that slows down disease progression and is reimbursed in Belgium since 2016. The other two innovations presented are, on one hand, the progress made in the diagnosis and follow-up of idiopathic membranous nephropathy, which is often of autoimmune nature, and on the other hand, the hope raised by living kidney donor exchange programs for patients awaiting transplantation.
Key words
Polycystic kidney disease, tolvaptan, membranous nephropathy, PLA2R, THSD7A, renal transplantation, living donor exchange program